Merck, Medarex, And Massachusetts In Deal | April 27, 2009 Issue - Vol. 87 Issue 17 | Chemical & Engineering News
Volume 87 Issue 17 | p. 15 | Concentrates
Issue Date: April 27, 2009

Merck, Medarex, And Massachusetts In Deal

Department: Business

Merck & Co. has licensed technology developed by biotechnology firm Medarex and the Massachusetts Biologic Laboratories at the University of Massachusetts Medical School for fighting infectious diarrhea. Paying $60 million upfront, Merck will get rights to CDA-1 and CDB-1, a fully human monoclonal antibody duo designed to neutralize the bacterial A and B toxins in Clostridium difficile infections. Medarex and MBL could split another $165 million in milestone payments as well as royalties from product sales by Merck. The antibody combination has completed Phase II clinical trials.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment